Indian pharma stocks fall after Trump's new drug tariffs
Sept 26 (Reuters) - Indian pharmaceutical stocks .NIPHARM fell 2.6% on Friday after U.S. President Donald Trump announced a 100% tariff on branded and patented drugs, effective October 1.
All 20 constituents of the index were lower as of 9:30 a.m. IST. Heavyweight Sun Pharmaceutical Industries SUN.NS fell 3.4%.
The U.S. takes slightly more than a third of India’s drug exports, mostly cheaper generics, which rose 20% to about $10.5 billion in fiscal 2025.
The near term impact of the tariffs is likely to be limited, as India mainly exports generics, ICICI Securities research analyst Pankaj Pandey said in a note.
"That being said, uncertainty still remains whether complex generics and biosimilars will come under tariff embargo in the future," Pandey added.
Related Articles
Alibaba – the Poster child of the Chinese AI Revolution
TradingKey - In the beginning of the year, Alibaba ADR at the New York Stock Exchange was traded at $84.95. AS of September 25th, the price is already $176.44, or more than double – a remarkable rally that doubled the price within less than ten months.
Carnival’s Q3 2025 Earnings Preview: Can Strong Demand and Celebration Key Drive Valuation Higher?
TradingKey - Fueled by robust consumer demand for cruise travel, Carnival has hit all-time highs in several key metrics, including revenue, yield, and customer deposits. Its stock has performed strongly in 2025, with a year-to-date gain exceeding 20% and a nearly 70% increase over the past 12 months
U.S. August PCE Preview: Four-Run PCE Bounce Challenges the Fed’s Three-Cut Plan
TradingKey - The U.S. Bureau of Economic Analysis (BEA) will release the August Personal Consumption Expenditures (PCE) Price Index on Friday, September 26, with markets closely watching how much tariff pass-through effects have influenced inflation.
U.S. August PCE: Inflation Remains the Market's Greatest Risk
Our baseline forecast anticipates sustained asset price increases. However, if inflation surpasses market expectations in the coming months, it could hinder further rate cuts and pose the greatest risk to financial markets.
Memory Giant Micron Delivers Stellar Q4 FY2025 with Explosive DRAM and HBM Growth
TradingKey - Micron Technology, Inc. (NASDAQ: MU) delivered a stellar Q4 FY2025 earnings report, exceeding expectations on revenue, earnings, and margins. The company reported total revenue of $11.32 billion, up 46% YoY and 22% sequentially, surpassing the consensus forecast of $11.1 billion.
